Drug Watch: Agents in late-stage development for the treatment of types 1 and 2 diabetes mellitus (September 2008)
What We are Reading: A Pioneer in GLP-1 Research Fights for Recognition
Svetlana Mojsov, Ph.D., was a key part of the team that discovered the function of the hormone glucagon-like peptide 1 (GLP-1) and its role in diabetes and weight loss.
KFF Survey: Consumers Want Insurance to Pay for Weight Loss Drugs
Almost half of adults surveyed by KFF would be interested in taking a weight-loss drug, including many who say they only want to lose a little weight.
Cost-Sharing Caps Boost Insulin Refills for Medicare Part D Enrollees
Researchers say capping insulin costs at $35 a month has the potential to lower events and costs related to diabetes, such as amputations, vision loss, and heart attacks.
Capital Rx Partners with Virta Health for Diabetes, Obesity Patient Support
Sara Izadi, Pharm.D., of Capital Rx, talks about Rx Reverse, an integrated clinical program designed to help members reverse diabetes and fight obesity.
Analysis: PBMs Block Access to Lantus Biosimilars
An analysis by Biosimilars Council has found that the reference product Lantus accounts for 54% of new prescriptions and is 78% of total market volume but demand for the unbranded interchangeable insulin glargine is increasing.
New Pediatric Growth Hormone Therapy Costs $8,300 Monthly
Longer-acting growth hormone reduces frequency of injections. It will be available in August.
2 Clarke Drive Cranbury, NJ 08512